JPWO2019006283A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019006283A5 JPWO2019006283A5 JP2020500206A JP2020500206A JPWO2019006283A5 JP WO2019006283 A5 JPWO2019006283 A5 JP WO2019006283A5 JP 2020500206 A JP2020500206 A JP 2020500206A JP 2020500206 A JP2020500206 A JP 2020500206A JP WO2019006283 A5 JPWO2019006283 A5 JP WO2019006283A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- free base
- cancer
- fluoroquinolin
- cyclohexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527855P | 2017-06-30 | 2017-06-30 | |
| US62/527,855 | 2017-06-30 | ||
| PCT/US2018/040262 WO2019006283A1 (en) | 2017-06-30 | 2018-06-29 | AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526520A JP2020526520A (ja) | 2020-08-31 |
| JPWO2019006283A5 true JPWO2019006283A5 (de) | 2025-03-14 |
| JP7690284B2 JP7690284B2 (ja) | 2025-06-10 |
Family
ID=64742242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500206A Active JP7690284B2 (ja) | 2017-06-30 | 2018-06-29 | Ｉｄｏ阻害剤の非晶質形態および結晶形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11236049B2 (de) |
| EP (1) | EP3644993B1 (de) |
| JP (1) | JP7690284B2 (de) |
| KR (1) | KR102630575B1 (de) |
| CN (1) | CN111093651B (de) |
| AU (1) | AU2018294314B2 (de) |
| BR (1) | BR112019027259A2 (de) |
| CA (1) | CA3066789A1 (de) |
| EA (1) | EA202090119A1 (de) |
| IL (1) | IL271601B2 (de) |
| MX (2) | MX391848B (de) |
| SG (1) | SG11201911937UA (de) |
| WO (1) | WO2019006283A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7315483B2 (ja) * | 2017-06-30 | 2023-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法 |
| EP3711387B1 (de) * | 2017-11-17 | 2024-06-26 | Telefonaktiebolaget LM Ericsson (publ) | Signalisierung von ta-offset in nr |
| CN110357813A (zh) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
| WO2020000236A1 (zh) * | 2018-06-27 | 2020-01-02 | 深圳仁泰医药科技有限公司 | (r)-n-(4-氯苯基)-2-(顺-4-(6-氟喹啉-4-基)环己基)丙酰胺的晶型 |
| EP4027980A1 (de) * | 2019-09-11 | 2022-07-20 | Bristol-Myers Squibb Company | Pharmazeutische formulierungen von indoleamin-2,3-dioxygenase-inhibitoren |
| MX2022006134A (es) * | 2019-11-26 | 2022-06-17 | Bristol Myers Squibb Co | Sales/cocristales de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroqu inolin-4-il)ciclohexil)propanamida. |
| AR120935A1 (es) * | 2020-01-02 | 2022-03-30 | Hutchison Medipharma Ltd | Derivados de amida y usos de los mismos |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| EA026785B1 (ru) | 2005-05-10 | 2017-05-31 | Инсайт Холдингс Корпорейшн | Модуляторы индоламин 2,3-диоксигеназы и способы их применения |
| ME02260B (me) | 2005-07-01 | 2016-02-29 | Medarex Inc | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| JP5294874B2 (ja) | 2005-12-20 | 2013-09-18 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環 |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (de) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Zytotoxischer monoklonaler Anti-LAG-3-Antikörper und seine Verwendung bei der Behandlung und Vorbeugung von Organtransplantatabstoßung und Autoimmunerkrankungen |
| CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (de) | 2007-10-05 | 2009-04-08 | Immutep | Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion |
| EP2227233B1 (de) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido-inhibitoren |
| KR20110013421A (ko) | 2008-05-29 | 2011-02-09 | 생-고뱅 생트레 드 레체르체 에 데투드 유로삐엔 | 알루미늄 티타네이트 함유 다공질 구조물 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MY188826A (en) | 2008-12-09 | 2022-01-06 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3023438B1 (de) | 2009-09-03 | 2020-03-11 | Merck Sharp & Dohme Corp. | Anti-gitr-antikörper |
| EP2493862B1 (de) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazolderivate als ido-hemmer |
| ES2557454T3 (es) | 2009-12-10 | 2016-01-26 | F. Hoffmann-La Roche Ag | Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización |
| MA34062B1 (fr) | 2010-03-04 | 2013-03-05 | Macrogenics Inc | Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées |
| EP2542587A1 (de) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antikörper gegen menschlichen csf-1r und ihre verwendung |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| TW202112827A (zh) | 2010-05-04 | 2021-04-01 | 美商戊瑞治療有限公司 | 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類 |
| KR101527297B1 (ko) | 2010-09-09 | 2015-06-26 | 화이자 인코포레이티드 | 4-1ｂｂ 결합 분자 |
| NO2694640T3 (de) | 2011-04-15 | 2018-03-17 | ||
| SMT201800294T1 (it) | 2011-04-20 | 2018-07-17 | Medimmune Llc | Anticorpi e altre molecole che legano b7-h1 e pd-1 |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| EP2791174B1 (de) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antikörper gegen menschlichen csf-1r und deren verwendungen |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| HK1208233A1 (en) | 2012-05-11 | 2016-02-26 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CA2882804A1 (en) | 2012-08-31 | 2014-03-06 | Brian Wong | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| JP7315483B2 (ja) * | 2017-06-30 | 2023-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法 |
-
2018
- 2018-06-29 MX MX2019014885A patent/MX391848B/es unknown
- 2018-06-29 KR KR1020207002491A patent/KR102630575B1/ko active Active
- 2018-06-29 EP EP18823337.3A patent/EP3644993B1/de active Active
- 2018-06-29 SG SG11201911937UA patent/SG11201911937UA/en unknown
- 2018-06-29 AU AU2018294314A patent/AU2018294314B2/en active Active
- 2018-06-29 BR BR112019027259-3A patent/BR112019027259A2/pt active Search and Examination
- 2018-06-29 WO PCT/US2018/040262 patent/WO2019006283A1/en active IP Right Grant
- 2018-06-29 IL IL271601A patent/IL271601B2/en unknown
- 2018-06-29 CA CA3066789A patent/CA3066789A1/en active Pending
- 2018-06-29 EA EA202090119A patent/EA202090119A1/ru unknown
- 2018-06-29 US US16/624,490 patent/US11236049B2/en active Active
- 2018-06-29 JP JP2020500206A patent/JP7690284B2/ja active Active
- 2018-06-29 CN CN201880044036.6A patent/CN111093651B/zh active Active
-
2019
- 2019-12-10 MX MX2021015656A patent/MX2021015656A/es unknown
-
2021
- 2021-12-16 US US17/553,434 patent/US20220169615A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7690284B2 (ja) | Ｉｄｏ阻害剤の非晶質形態および結晶形態 | |
| TWI865579B (zh) | Ｈｐｋ１抑制劑之固體形式 | |
| US11104682B2 (en) | Salts of TAM inhibitors | |
| JP2022058400A (ja) | 免疫調節剤としての複素環化合物 | |
| TWI867287B (zh) | 經吡啶基取代之側氧基異吲哚啉化合物 | |
| JP2018521121A (ja) | （ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状 | |
| JP2019528300A (ja) | インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法 | |
| WO2023122777A1 (en) | Oxime derivatives useful as t cell activators | |
| JPWO2019006283A5 (de) | ||
| TW202023562A (zh) | 喹唑啉化合物及其鹽酸鹽之結晶形態 | |
| JP2021535182A (ja) | ホスホイノシチド３−キナーゼ（ｐｉ３ｋ）阻害剤の結晶形態 | |
| EA041037B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| US20230052523A1 (en) | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide | |
| EA049146B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| KR20250019700A (ko) | 치환된 페닐 옥사졸론 화합물 | |
| WO2024254227A1 (en) | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound | |
| WO2024263853A1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent |